The Translation Problem
95% of drug candidates fail from animal studies to human approval. This represents one of healthcare's largest sources of wasted investment and delayed treatments.
The Translation Problem is Real
Validated research confirms the economic and clinical significance of drug development failures.
95% of drug candidates that show promise in animal studies fail in human trials.
The Phase II 'Valley of Death' claims over 70% of candidates.
Annual oncology failure costs exceed $70 billion.
Published Findings
Public research on AI in drug development
Key Research Themes
Genetic Evidence Matters
Genetically supported targets show higher success rates in clinical trials.
AI Shows Promise
Machine learning approaches demonstrate improvements in predicting clinical outcomes.
Integration is Key
Multi-dimensional data analysis improves prediction accuracy.
Industry Benchmarks
| Company | Achievement | Source |
|---|---|---|
| Insilico Medicine | Phase 2 validation published | Nature Medicine |
| Recursion Pharmaceuticals | Phase 2 programs advancing | Public announcements |
| Generate:Biomedicines | Phase 3 trials ongoing | Company announcements |
Industry Context
Based on published literature and public data
Industry benchmarks from public sources
Industry Improvements
Reported improvements from AI adoption in drug development
Industry Context
The drug development industry faces significant challenges with high failure rates. AI and machine learning approaches are being explored industry-wide to improve success rates and reduce development costs.